Insider filing · AMLX
James M Frates
Chief Financial Officer
profile →
Amylyx Pharmaceuticals, Inc.
AMLX · Healthcare · 20 filings in 24 months
ticker →
James M Frates sold $315K of Amylyx Pharmaceuticals (AMLX)
Executed Sep 10, disclosed Sep 14, 4 days later.
Value, as filed
$315K
9,768 sh × $32.27
Executed
Sep 10
the trade date, as filed
Disclosed
Sep 14
4 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JFJames M Frates (Chief Financial Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Amylyx Pharmaceuticals, Inc. (AMLX). The largest single filing was $315K of AMLX (9,768 sh × $32.27, as filed), executed Sep 10.
The name
AMLXHealthcare · Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for ne…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by James M Frates in AMLX
AMLXSALE
Amylyx Pharmaceuticals, Inc.
$115K7,909 sh × $14.52
Exec Mar 2
Filed Mar 4 · 5:30 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. $155K
10,558 sh × $14.65
Exec Sep 30 2025
Filed Oct 2 2025 · 5:30 PM ET AMLXPURCHASE Amylyx Pharmaceuticals, Inc. –
40,000 sh · price not plausible
Exec Sep 12 2024
Filed Sep 16 2024 · 5:30 PM ET